Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Abbott Laboratories has settled a lawsuit regarding pregnancy discrimination involving a former employee who was laid off. The case highlights issues of bias in the workplace, particularly concerning pregnant employees. While the article discusses the settlement, it does not provide specific details about the number of employees affected by layoffs or the circumstances surrounding them. The focus remains on the legal implications of the case rather than on broader layoffs within the company.
Abbott Laboratories has announced the layoff of approximately 300 employees at its facility in Galway, Ireland, effective October 1, 2023. The decision comes as part of a restructuring effort aimed at streamlining operations within the company. Abbott has cited the need to adapt to changing market conditions and improve efficiency as key reasons for the workforce reduction. The layoffs are expected to impact various roles within the facility, although specific departments affected have not been disclosed. This move reflects broader challenges faced by the medtech industry amid economic pressures.
Abbott Laboratories has informed its staff about job cuts at its Galway plant, affecting approximately 100 employees. This decision comes as part of broader organizational changes within the company. The layoffs are attributed to a restructuring plan aimed at improving operational efficiency. The company has emphasized its commitment to maintaining a strong presence in Ireland despite these reductions. The affected employees were notified on October 1, 2023, as part of the company's efforts to adapt to changing market conditions.
No one has shared a story from Abbott Laboratories yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.